Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD8701
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
AZD8701 is a next-generation antisense oligonucleotide (ASO) designed to selectively target and degrade forkhead box P3 (FOXP3) mRNA in regulatory T cells (Tregs). By reducing FOXP3 expression, AZD8701 impairs the immunosuppressive function of Tregs and enhances antitumor immune responses. This approach aims to relieve tumor-induced immunosuppression and promote anti-tumor activity in cancer patients. Developed as a first-in-class human clinical candidate for oncology indications, it has demonstrated potent dose-dependent knockdown of FOXP3 protein in preclinical models and early-phase clinical trials[2][5][8].
- Other names
- Foxp3 targeted antisense oligonucleotideFoxp-3 targeted antisense oligonucleotideFoxp 3 targeted antisense oligonucleotide
02
Targets
FOXP3 (Forkhead box protein P3)
Beyond the preview
Go deeper on AZD8701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD8701.